FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318561907> ?p ?o ?g. }

• W4318561907 abstract "The management of intra-abdominal abscesses complicating Crohn's disease (CD) is challenging, and surgery with delayed intestinal resection is often recommended. The aims of this study were to estimate the success rate of adalimumab (ADA) in patients with CD with an intra-abdominal abscess resolved without surgery, and to identify predictive factors for success.A multicenter, prospective study was conducted in biologic-naïve patients with CD with resolved intra-abdominal abscess treated with ADA with a 2-year follow-up. The primary endpoint was ADA failure at week (W) 24 defined as a need for steroids after W12, intestinal resection, abscess recurrence, and clinical relapse. Secondary post-hoc endpoint was the long-term success defined as the survival without abscess relapse or intestinal resection at W104. The factors associated with ADA failure at W24 and W104 were identified using a logistic and a Cox regression, respectively.From April 2013 to December 2017, 190 patients from 27 GETAID centers were screened, and 117 were included in the analysis. Fifty-eight patients (50%) were male, and the median age at baseline was 28 years. At W24, 87 patients (74%; 95% confidence interval [CI], 65.5%-82.0%; n = 117) achieved ADA success. Among the 30 patients with ADA failure, 15 underwent surgery. At W104, the survival rate without abscess recurrence or surgery was 72.9% (95% CI, 62.1%-79.8%; n = 109). Abscess drainage was significantly associated with ADA failure at W24 (odds ratio, 4.18; 95% CI, 1.06-16.5; P =0 .043). Disease duration (hazard ratio [HR], 1.32; 95% CI, 1.09-1.59; P = .008), abscess drainage (HR, 5.59; 95% CI, 2.21-14.15; P = .001), and inflammatory changes in mesenteric fat (HR, 0.4; 95% CI, 0.17-0.94; P = .046) were significantly associated with ADA failure at W104.Provided that the abscess was carefully managed before initiating medical treatment, this study showed the high efficacy of ADA in the short and long term in biologic-naïve patients with CD complicated by an intra-abdominal abscess.gov, Number: NCT02856763." @default.
• W4318561907 created "2023-01-31" @default.
• W4318561907 creator A5003276206 @default.
• W4318561907 creator A5004319820 @default.
• W4318561907 creator A5005987326 @default.
• W4318561907 creator A5012734445 @default.
• W4318561907 creator A5019014483 @default.
• W4318561907 creator A5022309322 @default.
• W4318561907 creator A5026868068 @default.
• W4318561907 creator A5029624621 @default.
• W4318561907 creator A5032705919 @default.
• W4318561907 creator A5034684382 @default.
• W4318561907 creator A5036870609 @default.
• W4318561907 creator A5038935670 @default.
• W4318561907 creator A5042386776 @default.
• W4318561907 creator A5042798131 @default.
• W4318561907 creator A5044343954 @default.
• W4318561907 creator A5044363342 @default.
• W4318561907 creator A5045364690 @default.
• W4318561907 creator A5047088415 @default.
• W4318561907 creator A5047625349 @default.
• W4318561907 creator A5052407408 @default.
• W4318561907 creator A5054209563 @default.
• W4318561907 creator A5054590261 @default.
• W4318561907 creator A5054952907 @default.
• W4318561907 creator A5054971479 @default.
• W4318561907 creator A5065655219 @default.
• W4318561907 creator A5068268866 @default.
• W4318561907 creator A5068930601 @default.
• W4318561907 creator A5070441072 @default.
• W4318561907 creator A5071109916 @default.
• W4318561907 creator A5076644360 @default.
• W4318561907 creator A5079162978 @default.
• W4318561907 creator A5079458166 @default.
• W4318561907 creator A5080833556 @default.
• W4318561907 creator A5081540419 @default.
• W4318561907 creator A5084003535 @default.
• W4318561907 creator A5088433879 @default.
• W4318561907 creator A5088583593 @default.
• W4318561907 date "2023-01-01" @default.
• W4318561907 modified "2023-10-17" @default.
• W4318561907 title "Adalimumab in Biologic-naïve Patients With Crohn’s Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID" @default.
• W4318561907 cites W1547943993 @default.
• W4318561907 cites W1870370526 @default.
• W4318561907 cites W1994597901 @default.
• W4318561907 cites W2018627586 @default.
• W4318561907 cites W2026044573 @default.
• W4318561907 cites W2041591626 @default.
• W4318561907 cites W2056587239 @default.
• W4318561907 cites W2060350127 @default.
• W4318561907 cites W2074932800 @default.
• W4318561907 cites W2094935750 @default.
• W4318561907 cites W2102252264 @default.
• W4318561907 cites W2112959584 @default.
• W4318561907 cites W2115865518 @default.
• W4318561907 cites W2320257037 @default.
• W4318561907 cites W2326330820 @default.
• W4318561907 cites W2580037380 @default.
• W4318561907 cites W2785248466 @default.
• W4318561907 cites W2809196018 @default.
• W4318561907 cites W2888061430 @default.
• W4318561907 cites W2942003336 @default.
• W4318561907 cites W2984128211 @default.
• W4318561907 cites W34258608 @default.
• W4318561907 doi "https://doi.org/10.1016/j.cgh.2023.01.013" @default.
• W4318561907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36731588" @default.
• W4318561907 hasPublicationYear "2023" @default.
• W4318561907 type Work @default.
• W4318561907 citedByCount "0" @default.
• W4318561907 crossrefType "journal-article" @default.
• W4318561907 hasAuthorship W4318561907A5003276206 @default.
• W4318561907 hasAuthorship W4318561907A5004319820 @default.
• W4318561907 hasAuthorship W4318561907A5005987326 @default.
• W4318561907 hasAuthorship W4318561907A5012734445 @default.
• W4318561907 hasAuthorship W4318561907A5019014483 @default.
• W4318561907 hasAuthorship W4318561907A5022309322 @default.
• W4318561907 hasAuthorship W4318561907A5026868068 @default.
• W4318561907 hasAuthorship W4318561907A5029624621 @default.
• W4318561907 hasAuthorship W4318561907A5032705919 @default.
• W4318561907 hasAuthorship W4318561907A5034684382 @default.
• W4318561907 hasAuthorship W4318561907A5036870609 @default.
• W4318561907 hasAuthorship W4318561907A5038935670 @default.
• W4318561907 hasAuthorship W4318561907A5042386776 @default.
• W4318561907 hasAuthorship W4318561907A5042798131 @default.
• W4318561907 hasAuthorship W4318561907A5044343954 @default.
• W4318561907 hasAuthorship W4318561907A5044363342 @default.
• W4318561907 hasAuthorship W4318561907A5045364690 @default.
• W4318561907 hasAuthorship W4318561907A5047088415 @default.
• W4318561907 hasAuthorship W4318561907A5047625349 @default.
• W4318561907 hasAuthorship W4318561907A5052407408 @default.
• W4318561907 hasAuthorship W4318561907A5054209563 @default.
• W4318561907 hasAuthorship W4318561907A5054590261 @default.
• W4318561907 hasAuthorship W4318561907A5054952907 @default.
• W4318561907 hasAuthorship W4318561907A5054971479 @default.
• W4318561907 hasAuthorship W4318561907A5065655219 @default.
• W4318561907 hasAuthorship W4318561907A5068268866 @default.
• W4318561907 hasAuthorship W4318561907A5068930601 @default.
• W4318561907 hasAuthorship W4318561907A5070441072 @default.
• W4318561907 hasAuthorship W4318561907A5071109916 @default.
• W4318561907 hasAuthorship W4318561907A5076644360 @default.

• next